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The innate immune response to cytosolic DNA involves transcriptional activation of
type I interferons (IFN-I) and proinflammatory cytokines. This represents the culmination
of intracellular signaling pathways that are initiated by pattern recognition receptors
that engage DNA and require the adaptor protein Stimulator of Interferon Genes
(STING). These responses lead to the generation of cellular and tissue states that
impair microbial replication and facilitate the establishment of long-lived, antigen-specific
adaptive immunity. Ultimately this can lead to immune-mediated protection from
infection but also to the cytotoxic T cell-mediated clearance of tumor cells. Intriguingly,
pharmacologic activation of STING-dependent phenotypes is known to enhance
both vaccine-associated immunogenicity and immune-based anti-tumor therapies.
Unfortunately, the STING protein exists as multiple variant forms in the human population
that exhibit differences in their reactivity to chemical stimuli and in the intensity of
molecular signaling they induce. In light of this, STING-targeting drug discovery efforts
require an accounting of protein variant-specific activity. Herein we describe a small
molecule termed M04 that behaves as a novel agonist of human STING. Importantly,
we find that the molecule exhibits a differential ability to activate STING based on
the allelic variant examined. Furthermore, while M04 is inactive in mice, expression of
human STING in mouse cells rescues reactivity to the compound. Using primary human
cells in ex vivo assays we were also able to show that M04 is capable of simulating
innate responses important for adaptive immune activation such as cytokine secretion,
dendritic cell maturation, and T cell cross-priming. Collectively, this work demonstrates
the conceivable utility of a novel agonist of human STING both as a research tool for
exploring STING biology and as an immune potentiating molecule.
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INTRODUCTION
The innate immune response is a rapid cell-based reaction
to microbial infection and diseased cellular states that
predominantly involves secretion of immunologically functional
cytokines. This results from activation of transcription factors
or proteolytic caspases at the terminus of intracellular signaling
cascades. These signaling pathways are initiated by pattern
recognition receptor (PRR) proteins that directly engage and
are induced by pathogen- or damage-associated molecular
patterns (PAMPs, DAMPs). Among the most potent cytokines
are the type I interferons (IFN-I) including IFNβ and multiple
IFNα subtypes. IFN-I bind to the nearly ubiquitous IFNα/β
receptor (IFNAR) which then activates via Janus kinases (JAK)
the transcription factors signal transducer and activator of
transcription 1 and 2 (STAT1/2) and IFN regulatory factor 9.
The IFNAR-JAK-STAT pathway leads to the transcription of
numerous IFN-stimulated genes (ISGs) that exhibit diverse
phenotypic effects including generation of antiviral states and
coordinating adaptive immunity (1). IFNs are thus essential for
combating infectious (especially viral) diseases, anti-tumor T cell
responses, and maintaining tissue homeostasis.
Synthesis of IFNβ mRNA specifically requires the
transcription factor IFN regulatory factor 3 (IRF3) (2).
Activation of this involves phosphorylation by the multi-target
kinase TANK binding kinase 1 (TBK1). This, in turn, is activated
by one of three adaptor proteins (TRIF, MAVS, and STING)
that serve as signal integrators from upstream PRRs (3).
Stimulator of IFN genes (STING, also called MITA, ERIS, MPYS,
TMEM173) is an ER-associated protein that functions as an
adaptor for signals from PRRs that react to cytosolic dsDNA
[reviewed in (4)]. Importantly, STING is itself a PRR engaged
by cyclic dinucleotides (CDNs) that are synthesized both during
bacterial infection as well as by cyclic GMP-AMP synthase
(cGAS), a cellular nucleotidyl transferase that is activated after
binding to cytosolic DNA (5–7). cGAS uses ATP and GTP to
produce a cyclic GMP-AMP molecule that contains G(2’,5’)pA
and A(3’,5’)pG phosphodiester linkages that engages the C-
terminal ligand binding domain (LBD) of dimerized STING
proteins. Upon ligand binding, STING recruits TBK1 which
phosphorylates STING, TBK1, and IRF3. Activated IRF3 then
translocates to the nucleus where it drives synthesis of mRNA
for IFNβ and a subset of ISGs, often in concert with other
transcription factors such as NF-κB (8) and STAT6 (9) that
potentiate expression of additional proinflammatory genes.
The STING-dependent activation of type I IFNs as well as
other pro-inflammatory cytokines generates cellular and tissue
states that are adverse for virus replication (10). Additionally,
transient and localized activation of STING can also lead
to stimulation of antigen presenting cell (APC) phenotypes
involving cytokine, effector, and costimulatory protein
expression that promote antigen uptake and processing and
lymph node trafficking, and ultimately facilitate establishment
of adaptive immune responses. As such, STING-dependent
processes are important for antibody and cytotoxic T cell-
mediated activity against infecting microbes as well as tumor
cells [reviewed in (11)]. Intriguingly, STING activation can be
triggered pharmacologically by synthetic small molecules and
engineered macromolecules (12). This represents a potentially
formidable strategy for eliciting broad-spectrum antiviral activity
(13), generating anti-tumor immunity (14), and enhancing
vaccine immunogenicity (15). In light of this, numerous
efforts are underway to discover novel and safe STING-based
immunomodulators that can be utilized for potentiating
desirable clinical outcomes. Unfortunately, significant STING
polymorphism exists in the human population, which affects
both the molecular responses induced by the protein’s activation
and the degree of sensitivity to stimulatory ligands (16).
Consequently, this can greatly impact the efficacy and safety
of molecular entities pursued for clinical purposes. Here we
describe a novel small molecule that activates the IFN-I response
by way of STING that is differentially active in naturally
occurring variants of the protein. In primary human cells this
compound is also capable of inducing innate activity that is
consistent with facilitation of adaptive immunity and as such
may represent a new STING-directed molecular entity with
clinical applications.
RESULTS
M04 Is a Small Molecule That Activates
Type I IFN Signaling in Human Cells
Previous work from our group described a high throughput
screen (HTS) undertaken to identify novel small molecules
capable of stimulating the type I IFN response in human cells
(17–19). From a library of >51,000 compounds, the second
most reactive hit was 2-(cyclohexylsulfonyl)-N,N-dimethyl-
4-tosylthiazol-5-amine (we term this M04 for simplicity;
Figure 1A), which has a MW of 428.6 and LogP of 4.17.
The original screen was performed on telomerase-transduced
human foreskin fibroblasts (THF) into which a reporter cassette
encoding the firefly luciferase (LUC) open reading frame
controlled by IFN-stimulated responsive elements (ISRE) was
also stably introduced. To validate the HTS results we therefore
measured LUC expression in these cells following exposure
to a range of M04 doses and, in parallel, cytotoxicity. As
shown in Figure 1B, LUC signal was maximal at 100µM with
only minimal loss in cell viability. To examine efficacy of the
molecule on human cells of a distinct ontology we employed
myeloid-derived MonoMac6 (MM6) cells (20). These were stably
transduced with the same ISRE-LUC reporter cassette and treated
with a similar range of M04 doses. As shown in Figure 1C, MM6-
ISRE exhibited higher sensitivity to M04 with maximum signal
observed at 25µM. While no detectable toxicity was observed at
that concentration, higher doses showed significant cell death.
While these data show thatM04 can clearly activate expression
of an artificial IFN-sensitive reporter, we next aimed to establish
whether the molecule is also capable of inducing transcription
of endogenous IFN-stimulated genes (ISGs). For this we exposed
MM6 cells to M04 as well as IFNβ and used semi-quantitative
reverse transcriptase PCR (qPCR) to measure induced levels of
IFIT1 (21) and Viperin (RSAD2) (22). As shown in Figure 1D,
M04 led to levels of IFIT1 and Viperin mRNA synthesis
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FIGURE 1 | Dose-Dependent Activation of Type I Interferon-Mediated Signaling and Cytotoxicity of M04 in Human Cells. (A) Chemical structure of
2-(cyclohexylsulfonyi)-N,N-dimethyl-4-tosylthiazol-5-amine (”M04"); (B) ISRE-dependent expression of Luciferase (LUC) as well as relative cellular viability as
determined by Cell Titer Glo in THF (B) and MM6 (C) cells exposed to M04 at indicated concentrations (µM) for 8 h (RLU) or 24 h (Cell Titer Glow). Values presented
are mean fold change ± SD relative to cells treated with 1% DMSO (RLU; black bars; left y-axis). Cell viability data are expressed as relative signal detected in
DMSO-treated cells (red squares; right axis). Values displayed are based on four replicates; (D) Fold changes of IFIT1 or Viperin mRNA relative to 1% DMSO treatment
in immortalized lymphatic endothelial cells (iLEC) or MM6 following 8 h exposure to 1000U/mL IFNβ or 50µM M04 as indicated. Presented values represent average ±
SD mRNA fold changes relative to cells exposed to untreated cells from duplicate experiments.
that resembled those induced by IFNβ. Since results thus far
indicated that M04 was able to trigger IFN-associated activity in
stromal and myeloid-derived cells, we next examined whether
an unrelated cell type was also responsive to the molecule. For
this we performed qPCR using immortalized human lymphatic
endothelial cells (iLEC) treated as described for MM6 and
observed similar levels of ISG induction (Figure 1D). Taken
together, these data indicate that M04 is a novel small molecule
capable of stimulating IFN-dependent responses across human
cell types in a dose dependent manner without significant
cytotoxicity at its active concentrations.
M04-Mediated Innate Stimulation Requires
Activation of TBK1 and IRF3
Conventional initiation of the type I IFN response involves
activation of the IRF3 transcription factor via phosphorylation of
serine residues by TBK1which then enables nuclear translocation
and transcription of IFNβ (23). To examine whether this
activity occurs following treatment with M04 we performed
immunoblotting (IB) using whole cell lysates from MM6 and
THF cells treated with M04 or the RIG-I/MAVS/IRF3-activating
stimulus Sendai virus (SeV) (24). As shown in Figure 2A, both
stimuli led to the phosphorylation of TBK1 and IRF3, indicating
inducible activation of both proteins. Since activated IRF3 must
accumulate in the nucleus to drive IFN and ISG transcription,
we next examined its subcellular localization using indirect
immunofluorescence assay (IFA). As shown in Figure 2B, THF
cells treated with M04 as well as the STING/IRF3 agonist
2’3’ cyclic GMP-AMP (cGAMP), but not the cytokine TNFα,
displayed obvious nuclear IRF3 protein, consistent with its
typical activated status.
While these data demonstrate standard activation of the
TBK1-IRF3 signaling axis, whether this is essential to the IFN-
associated innate induction triggered by M04 cannot be formally
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FIGURE 2 | M04 induces canonical activation of IRF3 which is essential to reporter signal generated by the compound. (A) Immunoblot showing phosphorylation
status of TBK1 Ser172 and IRF3 Ser386 as well as corresponding total protein levels in MM6 cells (left) and THF (right) exposed for 4 h to 1% DMSO, 50µM M04, or
1,000 HAU/mL SeV as indicated; (B) Indirect immunofluorescence showing subcellular localization of IRF3 in THF exposed for 4 h to 1% DMSO, transfected
2’3’cGAMP (10µg/mL), 100 ng/mL TNFα, or 50µM M04; (C) Reporter assay illustrating IFN-dependent LUC induction following overnight treatment with 1% DMSO,
1,000 U/mL IFNβ, 1,000 HAU/mL SeV, or 50µM M04 in parental cells as well as those from which IRF3 was deleted as indicated. Data presented are mean ± SD
relative luminescence units (RLU) using signal from DMSO-treated cells based on quadruplicate measurements. Student’s T-test was used to compare RLU in the
parental and 1IRF3 cells **P < 0.01; ***P < 0.001.
concluded. To address this, we utilized previously published
THF reporter cells from which the IRF3 protein was deleted
using CRISPR/Cas9-mediated genome editing (19). As shown
in Figure 2C, derivative mutant cells are capable of producing
reporter signal following treatment with IFNβ, which indicates
that JAK/STAT signaling is intact. However, neither SeV nor
M04 were able to elicit measurable reporter expression in these
cells indicating that IRF3 is required for the induction of IFN-
dependent signaling by both stimuli. Based on these data we
conclude that M04 stimulates type I IFN responses through the
canonical and necessary activation of TBK1 and IRF3.
M04 Does Not Stimulate Activation of
Canonical NF-κB-Associated Transcription
The transcription factor NF-κB is activated by signaling initiated
frommultiple PRRs (including many that are also IRF3-directed)
(25). Importantly, the protein also contributes to the expression
of numerous proinflammatory cytokines, including type I IFNs
(8, 9). Since M04 leads to conventional activation of IRF3, we
therefore asked whether it also stimulates NF-κB. To address
this we first exposed M04 to THF stably transduced with an
NF-κB-dependent LUC reporter as described (18). As shown in
Figure 3A, the compound was unable to activate LUC expression
in these cells at a range of doses, in contrast to stimuli known
to induce NF-κB such as SeV or the cytokine TNFα. Next, we
examined whether M04 could induce nuclear accumulation of
the NF-κB subunit proteins P50 and P65, a hallmark of canonical
activation. For this we exposed THF to DMSO vehicle, TNFα,
the STING ligand di-amidobenzimidazole (diABZI) (26), or M04
and used IFA to visualize subcellular localization of the proteins.
As shown in Figure 3B, TNFα, but neither diABZI nor M04 led
to nuclear localization of P65 and P50. Collectively, these data
indicate that M04 does not lead to activation of NF-κB.
M04 Activates IRF3 and IFN-Terminal
Signaling That Requires STING but Not
MAVS, TRIF, or dsDNA PRRs
Three separate signaling cascades are known to elicit TBK1-
IRF3 activation and these are defined by the adaptor proteins
MAVS, TRIF, and STING [see (3)]. We therefore explored
which, if any, of these proteins are required for M04-mediated
induction of IRF3 and IFN. We began by utilizing THF-ISRE
cell lines constructed previously that lack both MAVS and
TRIF (17). Figure 4A shows that cGAMP [a STING-inducing
IRF3/IFN activator (6, 7, 27, 28)] and M04 are able to elicit
LUC expression in these cells suggesting that neither TRIF nor
MAVS is required for their activity. We next examined whether
M04 could activate IRF3 phosphorylation or ISG expression in
these cells. In this case we included SeV as a control stimulus
to demonstrate knockout as well as linked amidobenzimidazole
(ABZI) as a control small molecule STING activator (26). As
shown in Figure 4B, M04 and ABZI, but not SeV, were able
Frontiers in Immunology | www.frontiersin.org 4 July 2020 | Volume 11 | Article 1430
Abraham et al. Novel STING Agonist
FIGURE 3 | M04 does not Activate NF-κB-Dependent Processes. (A) Reporter assay using THF cells responsive to activated NF-κB showing induction of LUC
expression following 8 h treatment with 160 HAU/mL SeV, 10 ng/mL TNFα, or the indicated concentration of M04. Values displayed are average fold changes (±SD)
based on four replicates compared to DMSO-treated cells; (B) Indirect immunofluorescence showing subcellular localization of NF-KB P65 subunit in THF exposed for
4 h to DMSO, 100 ng/mL TNFα, or 75µM M04. Statistical significance between treated and untreated cells was then calculated using Student’s T-test ****p < 0.0001.
to induce IRF3 phosphorylation. These results strongly suggest
that both MAVS and TRIF are dispensable for M04-mediated
IFN induction but that STING may play an important role. To
address this issue we employed THF-ISRE from which STING
was deleted (17–19). While the reporter cassette in these cells
was reactive to IFNβ and SeV as expected, it was not induced by
M04 (Figure 4C). Moreover, while SeV led to phosphorylation
of IRF3 in these cells, neither M04 nor ABZI elicited a similar
response (Figure 4D). To examine this further we assessed type
I IFN secretion using a reporter cell-based bioassay on media
from treated parental THF as well as those lacking MAVS
and TRIF or STING as described (17). We exposed the cells
to DMSO, SeV, transfected cGAMP, or M04 and measured
secretion of all bioactive type I IFNs using a reporter-based
assay. As expected, parental cells secreted IFN-I in response to
the three innate stimuli (Figure 4E). Furthermore, MAVS/TRIF-
deficient cells did not respond to SeV but were reactive to
cGAMP and M04 while STING-deficient cells produced IFN-I in
response to SeV but not cGAMP or M04. To explore the innate
induction ability of M04 relative to other IRF3-terminal stimuli,
we also performed a dose response on THF-ISRE that included
SeV (MAVS agonist) and human cytomegalovirus (HCMV;
STING agonist). As shown in Supplemental Figure 1, maximum
activation by M04 approximates that induced by HCMV at an
MOI of 0.25 and is higher than that induced by SeV at up to 160
HA units/mL.
These results indicate that STING, but not MAVS or TRIF
is required for M04-mediated innate activation. STING is
fundamentally involved in the innate intracellular response to
cytosolic dsDNA (10, 29–31). In addition, multiple dsDNA-
reactive PRRs including cGAS (32), DDX41 (33), IFI16 (34), and
DAI/ZBP1 (35) are known to be associated with or upstream of
STING-dependent responses. We therefore next asked whether
M04-induced activity required any of these proteins. For this,
RLU was measured using previously described THF-ISRE cells
lacking each individual PRR after exposure to M04 (17). As
shown in Figure 4F, M04 was active on all these cell lines,
indicating that none of the deficient proteins are singularly
essential for the compound’s effects. Based on these results we
conclude that M04 activates an IRF3- and IFN-terminal innate
immune response in a manner that requires STING but not
MAVS, TRIF, or canonical dsDNA PRRs.
Frontiers in Immunology | www.frontiersin.org 5 July 2020 | Volume 11 | Article 1430
Abraham et al. Novel STING Agonist
FIGURE 4 | Innate Activation by M04 requires STING but not MAVS, TRIF, or cytosolic DNA PRRs. (A) Reporter assay illustrating IFN-dependent LUC induction in
THF-ISRE-1MAVS/TRIF following overnight treatment with 1% DMSO, transfected cGAMP (10µg/mL), or 75µM M04. Data presented are mean ± SD relative
luminescence units (RLU) using signal from DMSO-treated cells as the basis (n = 4 treatments); (B) Immunoblot showing phosphorylation status of IRF3 Ser386, total
IRF3, and GAPDH in THF-ISRE-1MAVS/TRIF following 8 h treatment with 1% DMSO, 75µM M04, 1,000 HAU/mL SeV or 25µM ABZI as indicated; (C) Reporter
assay illustrating IFN-dependent LUC induction in THF-ISRE-1STING following overnight treatment with 1% DMSO, 1,000 U/mL IFNβ, 1,000 HAU/mL SeV, or 75µM
M04. Data presented are mean RLU ± SD as described above; Student’s T-test was used to compare RLU ***p < 0.001; (D) Immunoblot showing phosphorylation
status of IRF3 Ser386, total IRF3 in THF-ISRE-1STING following 4 h treatment with 1% DMSO, 50µM M04, 1,000 HAU/mL SeV or 25µM ABZI as indicated; (E)
Secretion of bioactive type I IFN from parental THF as well as THF-ISRE-1MAVS/TRIF and THF-ISRE-1STING treated in triplicate overnight with 1% DMSO, 1,000
HAU/mL SeV, transfected cGAMP (10µg/mL), or 75µM M04. Data are expressed as mean concentrations ± SD for IFNβ equivalent units. Statistical significance
between treated and untreated cells of similar genetic background was calculated using Student’s T-test. ****p < 0.0001; (F) Reporter assay from WT parental
THF-ISRE cells as well as from cells from which indicated dsDNA-specific PRRs were deleted. Values presented are mean fold changes ± SD for duplicates relative to
the value for DMSO-treated cells.
M04 Induces Phosphorylation and
ER-Golgi Trafficking of STING
Canonical activation of STING involves phosphorylation of
serine residue 366 (36) followed by translocation from the
ER to the Golgi apparatus (37). Since M04 requires STING
for IRF3 activation we predicted that the compound leads to
these two outcomes. As shown in Figure 5A, immunoblots on
whole cell lysates from MM6 and THF cells treated with M04
or ABZI displayed phosphorylation of STING Ser366 whereas
lysates from untreated or SeV-treated cells did not. We next
performed IFA to examine co-localization of STING with the
standard Golgi protein marker GM130. Figure 5B shows that
transfection of THFs with cGAMP or treatment with M04 leads
to accumulation of STING in regions that also stain positive
for GM130. These results are consistent with conventional
intracellular activation of STING in response to M04. Since M04
induces IRF3 independently of any examined dsDNA PRRs or
cGAMP synthesis, we next explored whether observations could
be obtained that indicate direct interaction between the molecule
and the STING protein. This was performed as part of previous
studies measuring thermal shift of purified STING C-terminal
domain (CTD) that includes the ligand binding domain (LBD)
(17, 19).We expect that direct contact between the protein and an
examined ligand will lead to an increase in the protein’s thermal
stability that is observable as emission of protein-associated
SYPRO Orange at higher temperatures than those in the absence
of the ligand (27, 38). As shown in Figure 5C, incubation of
purified STING-CTD with cGAMP led to an increase in the
temperature at which fluorescence was emitted relative to that
with DMSO alone. However, the presence of M04 did not lead
to a significant increase in such temperatures relative to that
induced by DMSO. These results are not consistent with M04
directly interacting with STING-LBD as does cGAMP. While
direct interaction cannot formally be ruled out, determining
whether M04 activates STING by engaging the CTD in a manner
that does not affect thermal stability or by engaging a region
outside the CTD will require different experimental approaches
such as affinity tagging and protein pulldown. Unfortunately, the
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FIGURE 5 | M04 Induces Canonical STING Activation. (A) lmmunoblot showing phosphorylation status of STING Ser366 as well as total STING in THF and MM6
following 4 h treatment with 1% DMSO, 50µM M04, 1,000 HAU/mL SeV or 25µM ABZI as indicated; (B) Indirect immunofluorescence showing subcellular localization
of Golgi marker GM130 and STING in THF exposed for 4 h to DMSO, transfected cGAMP (10µg/mL), 100 ng/mL TNFα, or 50µM M04; (C) Melting temperature shifts
for human STING-CTD in the presence of DMSO, 75µM M04, or 100µM 2’3’ cGAMP. Data presented are SYPRO orange relative fluorescent units (RFU).
innate activity ofM04 is highly sensitive to chemical modification
as indicated by the absence of ISRE activity in a group of 13
M04 derivatives as shown in Supplemental Figure 2. As such,
adding moieties such as biotin to M04 will likely not represent
appropriate pulldown bait.
M04 Stimulatory Capacity Is Dependent on
STING Polymorphic Variant
In human populationsmultiple amino acid variants of STING are
known to exist and these can be mechanistically associated with a
range of phenotypic outcomes at the levels of molecular function
and disease state [reviewed in (39)]. Since both THF and MM6
cells exhibit the most common and CDN-reactive STING allele
(STING-WT), we chose to examine M04 activity in the presence
of another variant. For this we used THP-1 promonocytic cells,
which possess the R71H-G230A-R293Q (STING-HAQ) allele
(7, 16, 40). We first used commercially available, IFN-sensitive
THP-1-ISG-Lucia reporter cells. LUC signal was produced by
these cells when exposed to SeV, IFNβ, a small molecule agonist
of the TRIF pathway termed AV-C (18), but not M04 nor,
interestingly, ABZI (Figure 6A). These results suggest that THP-
1 cells are not responsive to these two compounds and this
was validated by immunoblotting which showed that while SeV
treatment led to S386-phosphorylated IRF3, neither M04 or
ABZI did (Figure 6B). However, the cells were able to react
to cGAMP, indicating that STING signaling is operational in
these cells (Figure 6B). Based on this we hypothesized that
the endogenous STING-HAQ protein was incapable of reacting
to M04 and decided to ask whether ectopic expression of
STING-WT could rescue M04 responsiveness in THP-1 cells.
To pursue this, we first employed CRISPR/Cas9 to construct a
THP-1 line from which the endogenous STING-HAQ protein
was deleted and then used a lentivector to stably introduce
into these edited cells a constitutively expressed open reading
frame encoding the STING-WT protein (Figure 6C). These
cells were then treated with SeV, M04, ABZI, or cGAMP and
immunoblotting performed to examine IRF3 phosphorylation.
As shown in Figure 6D, expression of STING-WT rendered the
cells responsive to M04, suggesting that the compound is able to
stimulate activity of this, but not the HAQ protein variant.
To verify the differential responsiveness of the protein
variants to M04 using an independent method, we employed
transiently transfected HEK293T cells. These cells are deficient
in endogenous STING and as such will only respond to
STING inducers during ectopic expression of the protein (29,
31). We constructed plasmid vectors that encode STING-
WT, STING-HAQ, or STING-R232H (the third most common
STING variant). We then transfected these along with a IFN-
responsive LUC reporter vector and exposed the cells to DMSO,
M04, cGAMP, or diABZI, a derivative of ABZI shown to
be reactive with STING-HAQ (26). We then examined IRF3
phosphorylation and measured LUC expression from whole
cell lysates. As shown in Figure 7A, while transfection of the
vectors alone did not activate IRF3 phosphorylation, all three
stimuli led to phosphorylation of IRF3 in the presence of
STING-WT. However, M04 and diABZI elicited only weakly
detectable phosphorylation in the presence of STING-HAQ.
Furthermore, cGAMP appeared to induce a strong response
in the presence of STING-HAQ and STING-WT but not
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FIGURE 6 | Responsiveness to M04 can be Conferred through Introduction of WT STING Allelic Variant. (A) Reporter assay illustrating IFN-dependent LUC induction
in THP-1-ISG-Lucia following overnight treatment with 1% DMSO, 1,000 HAU/mL SeV, 1,000 U/mL IFNβ, 75µM TRIF agonist AV-C, 25µM ABZI, or 75µM M04.
Data presented are mean ± SD relative luminescence units (RLU) using signal from DMSO-treated cells as the basis (n = 4 treatments). Student’s T-test was used to
compare RLU ***p < 0.001, ****p < 0.0001; (B) lmmunoblot showing phosphorylation status of IRF3 Ser386 and total IRF3 in THP-1 whole cell lysates following 4 h
treatment with 1% DMSO, 50µM M04, 1,000 HAU/mL SeV, 25µM ABZI, or 10µg/mL cGAMP as indicated; (C) lmmunoblot showing expression of endogenous or
ectopically expressed WT hSTING in THP-1 as indicated. (D) Immunoblot showing phosphorylation status of IRF3 Ser386 in THP-1 cells from which endogenous
STING was deleted and WT STING stably introduced following indicated treatment as described above.
STING-R232H (Figure 7B). This was surprising but consistent
with results showing that this allele is comparatively less
responsive to cGAMP (7, 16). These results were reflected in the
IFN-dependent reporter signal with M04 and diABZI generating
detectable signal in the presence of STING-WT and STING-
R232H but weak or no signal in STING-HAQ transfected cells
and cGAMP inducing highest LUC signal in STING-WT and
STING-HAQ. These results also align with those generated in
THP-1 cells.
A549 lung epithelial cells suppress expression of the
endogenous STING mRNA (41) and, consequently, do not
respond to M04 (Figure 7C). We therefore asked whether
stable introduction of STING into these cells using methods
described above could also rescue M04 responsiveness. As shown
in Figure 7C, stable expression of hSTING-WT restores M04-
associated ISG expression. Results described so far including
these suggest that M04 activates STING in a manner that is
independent of DNA PRRs (Figure 4F) and binding to the
protein’s CTD (Figure 5C). To rule out the unlikely possibility
that M04 stimulates cGAS-independent synthesis of cGAMP we
treated A549 cells with M04 and harvested lysates to measure
cGAMP by ELISA. Figure 7D shows that while infection with
HCMV induces cGAMP synthesis as described (42), treatment
with M04 does not. Collectively, our results indicate that M04
activates STING in a cGAMP-independent manner either by
directly engaging the protein or by stimulating a cellular factor
common to THP-1, HEK293T, and A549 cells that regulates
STING function.
hSTING Confers Responsiveness to M04
Across Species
Given that the efficacy of M04 associates with amino acid
polymorphisms in the human STING allele, we believed it
unlikely that the compound triggers an innate response in
mouse cells. To address this, we first examined a commercially
available RAW264.7 murine macrophage-like line that expresses
an IFN-dependent reporter (RAW264.7-ISG-Lucia). In these,
SeV and DMXAA [a mouse-specific STING agonist (43)], but
not M04 were able to induce reporter expression (Figure 8A).
To examine whether the compound might still be active in an
in vivo setting, we injected it intraperitoneally into C57BL/6
mice and harvested spleens after 5 h. While DMXAA was able
Frontiers in Immunology | www.frontiersin.org 8 July 2020 | Volume 11 | Article 1430
Abraham et al. Novel STING Agonist
FIGURE 7 | Transient transfection of vectors encoding WT and R232H but not HAQ hSTING confer responsiveness to M04. (A) lmmunoblot from HEK293T whole
cell lysates showing expression of indicated STING variants following transient transfection, S386 phosphorylation status of IRF3 and total IRF3. Cells were left
untreated or exposed to 75µM M04, 100 nM diABZI, or 10µg/mL cGAMP as indicated; (B) Reporter assay using cells (n = 4) treated as described in (A). Values
displayed are mean fold changes ± SD relative to cells transfected with empty vector; (C) Expression of IFIT1 and Viperin mRNA as determined by qPCR in parental
A549 cells as well as those transduced with hSTING following treatment with 1% DMSO or 75µM M04. Data are mean fodl changes ± SD relative to DMSO-treated
cells based on duplicates; (D) Synthesis of cGAMP by A549-hSTING cells as determined by ELISA following overnight treatment with 1% DMSO, HCMV, or M04.
Data presented are mean pg/mL ± SD based on duplicate samples. Student’s T-test was used to compare RLU and mRNA levels ***p < 0.001, ****p < 0.0001.
to induce expression of Viperin and IFIT1 relative to DMSO-
vehicle treated control mice, we observed no upregulation of
these genes in response to M04 (Figure 8B). Since previous
work has demonstrated functionality of hSTING in mouse
cells (44), we next utilized a delete-and-replace approach as
described above to see if responsiveness to M04 could be
conferred to RAW264.7 cells by ectopic expression of hSTING-
WT. Figure 8C shows expression of endogenous or human
STING-WT in parental RAW264.7 cells as well as following
CRISPR-mediated knockout and target hSTING protein stable
introduction by lentivector. These cells were then exposed to
DMSO, M04, SeV, or cGAMP. As shown in Figure 8D, SeV
and cGAMP led to similar levels of phosphorylation IRF3 on
serine residues 379 and 396. Surprisingly, however, M04 did not
elicit detectable phosphorylation of IRF3 in either cell type. Since
it is possible that IRF3 is activated by phosphorylation of C-
terminal serine residues not detectable by available antibodies,
we also examined M04-mediated induction of ISGs in these
cells. As shown in Figure 8E, the compound induced minimal
or no ISG expression in parental cells but substantial amounts
in cells expressing hSTING. From these data we conclude that
M04 leads to hSTING effects that can activate innate responses in
non-human cells.
M04 Is Able to Elicit Secretion of
Pro-inflammatory Cytokines From Primary
Human Cells
STING agonism represents a potentially impactful
pharmacologic strategy in the context of facilitating adaptive
immune responses. However, thus far we only describe induction
of STING-dependent responses in immortalized or telomerized
cell lines. We therefore wished to determine whether M04
could activate innate phenotypes relevant for clinical uses.
However, since M04 is inactive in conventional murine models,
tractable options for exploring in vivo effects are not available.
In light of this, we chose to utilize human peripheral blood
mononuclear cells (PBMCs) to explore M04-mediated cellular
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FIGURE 8 | Responsiveness to M04 can be conferred to murine cells by ectopic expression of human STING-WT variant. (A) Reporter assay illustrating
IFN-dependent LUC induction in RAW264.7-ISG-Lucia cells followni g overnight treatment with 1% DMSO, 160 HAU/mL SeV, 25µM DMXAA, or 75µM M04.Data
presented are mean ± SD relative luminescence units (RLU) using signal from DMSO-treated cells as the basis (n = 4 treatments); (B) qPCR examining in vivo ISG
induction following IP injection of DMXAA or M04; (C) lmmunoblot showing expression of endogenous or ectopically expressed hSTING-WT in RAW264.7 cells as
indicated; (D) lmmunoblot showing phosphorylation status of IRF3 Ser379 and Ser396 as well as total IRF3 in RAW264.7-hSTING cells following 4 h treatment with
1% DMSO, 75µM M04, 160 HAU/mL SeV, or transfection of cGAMP as indicated; (E) qPCR examining transcription of IFIT1 or Viperin following overnight treatment
of parental RAW264.7 and RAW264.7-hSTING cells with 75µM M04 (n = 3). Data presented are mean fold changes ± SD of mRNA relative to cells treated with 1%
DMSO.
outcomes. Since STING agonists are being pursued clinically
as anti-cancer immunotherapeutics (45), we evaluated the
response of a relevant population of patients with locally
advanced or borderline resectable pancreatic cancer (46). PBMC
isolated from patients prior to treatment were exposed to
M04 overnight and media harvested for a multiplex assay to
measure cyto/chemokines secreted in response to treatment.
Cells were also left untreated, exposed to cyclic di-AMP (CDA)
as a STING-specific positive control, or LPS as a STING-
independent, IRF3-stimulating control. As shown in Figure 9,
M04 significantly induced secretion of TNFα, IL-1β, IL12p70,
and IL-10. Moreover, the patterns of M04-associated induction
more closely resembled those observed for CDA than LPS,
consistent with STING dependence of the two stimuli. Based
on this we conclude that M04 is capable of inducing innate
responses in primary human cells.
M04 Triggers Expression of Human
Dendritic Cell Maturation Markers
Dendritic cells (DC) are essential for the establishment of
adaptive immunity based on their capacity to present antigens
and secrete immunologically potent cytokines. This process
first involves their maturation, as denoted by surface marker
expression, in response to appropriate innate immune stimuli
that are often indicative of microbial infection or diseased
cells. We therefore asked whether M04 was capable of eliciting
induction of maturation markers on human cells. For this we
employed PBMCs from six healthy human donors in an ex vivo
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FIGURE 9 | Induction of cytokine expression by M04 on human primary cells. Peripheral blood mononuclear cells were harvested from ten human donors and treated
overnight with 1OO ng/mL LPS, 10 µg/mL cyclic di-AMP (CDA), or 75µM M04 as indicated. Luminex multiplex assay was then used to measure levels of TNFa,
IL-10, IL-1β, or IL12p70 in cell culture supernatant. Donor specific data are indicated by colored circles. Statistical significance between treated and untreated cells
was then calculated using Student’s T-test. *p < 0.5, **p < 0.01, ***p < 0.001; ****p < 0.0001.
culture system. Immature monocyte-derived DCs cultured in IL-
4 and GM-CSF were treated with two doses of M04. Control
stimuli included DMSO (negative) and LPS + IFNγ (positive).
Flow cytometry was then used to quantify expression of CD40,
HLA-DR, CD80, CD83, and CD86. As shown in Figure 10,
expression of HLA-DR and CD86 were significantly elevated
after M04 exposure relative to vehicle-treated cells. Surprisingly,
however, the compound did not similarly induce CD40, CD80,
or CD83. These results suggest that M04 behaves as an innate
stimulus that is capable of facilitating maturation of APCs and
may thus exhibit adjuvant properties.
M04 Enables T Cell Cross Priming
Potent and adequate CD8+ T cell responses against a specific
antigen is a key component of the adaptive immune response.
Induction of such high-quality T cell responses is crucial
for many vaccination objectives. Adjuvants can enhance the
function of antigen presenting cells, which through the priming
process, will shape the immune response and induce naïve
antigen-specific CD8+ T cells into potent effector cytotoxic
T lymphocytes. In an ex vivo assay using cryopreserved and
unfractionated PBMCs adapted from (47), we recapitulated the
priming, by dendritic cells, of CD8+ T cells specific for the model
antigenMelan-A, in the presence ofM04. Antigen-specific CD8+
T cells were detected by Melan-A-tetramer staining. As shown
in Figure 11, both M04 and cGAMP induce significantly higher
frequencies of primed Ag-specific CD8+ T cells compared to the
coculture without adjuvant. A 4.5-fold increase was observed in
the presence of M04 while cGAMP enhanced this by 3.3 times
the frequency of Ag-specific CD8+ T cells. These results thus
further demonstrate the adjuvant potential of M04 in human
primary cells.
The M04 Transcriptome More Closely
Resembles That Induced by cGAMP Than
by LPS
Given the ability of M04 to induce STING-dependent
transcription of targeted ISGs as well as innate phenotypes in
primary human cells, we predicted the stimulation of substantial
global transcriptional responses by the molecule in PBMCs.
We also expected that qualitatively these would more closely
resemble those triggered by an agonist of the STING pathway
relative to another IRF3-terminal adaptor. To address this, we
obtained PBMCs from two healthy human donors and treated
them with DMSO vehicle, M04, cGAMP, or the TLR4/TRIF
agonist LPS. RNA sequencing was then used to measure
individual transcript levels in each sample and comparisons to
vehicle-treated cells made (Supplemental Table 1). As shown
in Figure 12, M04, cGAMP, and LPS led to the significant more
than 2-fold upregulation of 314, 848, and 704 RNA transcripts,
respectively. Importantly, however, the number of transcripts
induced by M04 that were also uniquely upregulated by the
other stimuli was much greater for cGAMP than for LPS (76
vs. 7, respectively). Furthermore, the quantitative similarity
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FIGURE 10 | M04 induces HLA and costimulatory molecule upregulation on human monocyte-derived dendritic cells. Human monocyte-derived dendritic cells (DCs)
differentiated from healthy human PBMCs were treated with 1% OMSO or stimulated with 0.5µg/ml LPS plus 40 ng/ml IFN-y and 25µM or 50µM M04 for 24 h. DCs
were harvested (% DCs indicated PBMCs indicated at left) and analyzed by flow cytometry for the upregulation of surface C040, HLA-DR, CD80, CD83, and CD86 as
indicated. Values are presented as mean ± the standard deviations (mean ± SD) for the indicated marker from 6 individual donors across 3 independent experiments
(donor-specific values are represented by closed circles). *p < 0.5, **p < 0.01, ***p < 0.001.
in absolute fold changes of all observed transcripts was much
higher between M04 and cGAMP (Pearson r = 0.7554) than
betweenM04 and LPS (r= 0.6141) (Figure 12C). Finally, despite
the failure of experiments to show canonical activation of NF-κB
by M04 in fibroblasts, treatment of PBMCs with the compound
led to induction of multiple RNAs whose transcription was
predicted by two different computational tools (PASTAA and
RegulatorTrail) to be associated with activity of this transcription
factor (Supplemental Tables 2 and 3) (48, 49). This is consistent
with previous work describing NF-κB activation by STING
(8, 50, 51). We hypothesize that our results likely represent
a phenomenon related to intrinsic differences in cell type
whereby stromal and non-stromal cells are differentially reactive
to NF-κB-associated, STING-mediated pro-inflammatory
responses. This will require follow up mechanistic efforts to
dissect, however.
DISCUSSION
The innate and adaptive immunostimulatory potential of
synthetic STING activation has greatly incentivized the discovery
and characterization of novel molecular entities that stimulate
this pathway for anti-cancer therapies (45, 52) and as a strategy to
enhance vaccination (53, 54). Currently the most clinically well-
developed STING inducers are dithio-mixed linkage derivatives
of cyclic dinucleotides such as ML-RR-S2 CDA (also known
as ADU-S100) that are in clinical trials (NCT03172936) (55).
Unfortunately, CDNs exhibit chemical liabilities including
violation of Lipinski rules (56) for druglikeness, susceptibility to
phosphodiesterase-mediated degradation (57, 58), and their size,
hydrophilicity, and negative charge render them impermeable
to cell membranes thus impairing exposure to cytosolic STING
(59, 60). In general, the properties of small molecules such
as M04 mitigate these issues and, as such, may ultimately
represent a superior strategy for activating STING-mediated
processes in vivo.
Our work demonstrates that M04 activates an innate
response in human cells that requires STING and IRF3 but
not an array of other described cytosolic PRRs of DNA
(in particular cGAS). M04 also does not induce synthesis
of cGAMP by a cGAS-dependent or independent process.
Moreover, in addition to the loss of function approach used to
demonstrate protein essentiality, we also used forward genetics
methods that demonstrated conference of M04 responsiveness
to non-responsive cells (including mouse cells) following ectopic
expression of hSTING. These results strongly argue that the
compound’s mechanism of action involves direct engagement of
the STING protein. Why thermal shift analysis showed no M04-
mediated enhancement of STING-CTD stability is not clear but it
is possible that the compound binds to a protein domain outside
this region that leads to activation.
We also show that M04 is capable of inducing innate
activation in a manner that requires specific variants of human
STING. Surprisingly, diABZI showed similar patterns of allele-
specific efficacy with poor responsiveness in STING-HAQ and
normal activity in STING-R232H and STING-WT. This result
is actually inconsistent with what was previously shown for
diABZI in primary human cells homozygous for these alleles (26).
Whether this disparity is associated with the cell type or model
system we employed will require additional follow up studies.
Overall, however, these data suggest that it is possible to identify
small molecules that exhibit allele-specific activity, which may be
important given the existing STING polymorphism in the human
population (39). Interestingly, the alleles with which M04 and
diABZI function best encode arginine or histidine amino acids at
position 232 and arginine at position 293, which are both within
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FIGURE 11 | In vitro CD8+ T cell priming using unfractionated PBMC.
Dendritic cell differentiation from healthy HLA-A2+ donor PBMCs (n = 7) was
induced with GM-CSF (100 ng/ml) and IL-4 (20 ng/ml) and Melan A peptide
(1O µg/ml) with M04 (50µM) or 2,3’ cGAMP (5µg/ml) was added the next day
when indicated. On day 11, the primed Metan-A specific CD8+ T lymphocytes
were detected using tetramer staining within the CD3+ T cell population after
aggregates and dead cell exclusion. The graph represents the fold increase of
Metan-A - specific CD8+ T lymphocytes frequency compared to the condition
without STING agonists. A non-parametric Friedman signed rank test followed
by Dunn’s multiple comparison test was used to assess significance.
*p < 0.05.
the LBD. STING-HAQ differs from these alleles by encoding
glutamine at position 293, alanine at 230 and histidine at position
71, which is in the transmembrane domain. Whether any of
these individually are associated with our observations regarding
M04 or diABZI activity will require additional examination.
Furthermore, there exist other naturally occurring variants that
exist with relatively high frequency that we also plan to examine.
Surprisingly absent from the archive of studies examining the
clinical value of STING agonists is exploration of genetic impacts.
Given the breadth and frequency of human polymorphism in this
protein as well as links between phenotype and variant, a more
penetrative consideration of how this will affect STING-based
therapeutics is clearly warranted. Understanding the spectrum of
allele-associated molecule reactivity will be a very important step
in the development of STING-directed pharmacophores.
It is worth noting that while STING activation is known
to facilitate establishment of an adaptive immune response, its
overall immune impact is more nuanced. In some models the
protein is associated with tolerogenic responses likely through
its induction of indoleamine 2,3-dioxygenase, as observed in
our transcriptomic data for both M04 and cGAMP (61, 62).
However, determining with precision the immune-mediated
effects conferred by M04 and whether they have potential
clinical utility is hindered by its inactivity in mice. Fortunately,
primary human cells do display responses to M04 such as
cytokine secretion, expression of DC maturation markers, and
T cell cross-priming that associate with conventional immune
activity. Previous work has identified similar phenomena induced
by CDN-based agonists (63–65) as well as dsDNA (66) and
diABZI (26). Why some of the DC markers were not induced
as expected is unclear and could be related to donor-specific
effects such as STING genotype or a skewed set of molecular
processes induced in primary tissues by the compound. The key
question regarding M04 in this regard is whether the innate
processes induced by the molecule ex vivo would translate
into meaningful immunological effects in vivo. If M04 elicits
activity by binding directly to STING as we predict, obtaining
this answer may be possible in mice that express hSTING.
Previous work has shown that hSTING is functional and
responsive to activating ligands in mouse cells (44). It is
therefore possible that replacement of the endogenous mouse
STING with a human allele could lead to an animal model
useful for characterizing molecules with human but not mouse
specificity (17, 19, 67). Accordingly, this would greatly expand




Dimethyl sulfide (DMSO) was purchased from Thermo
Fisher. Human recombinant IFNβ was obtained from PBL.
Lipopolysaccharide (LPS) was obtained from Sigma. cGAMP
was obtained from Invivogen. Stocks of M04 were originally
obtained from Enamine. Larger stocks of M04 and ABZI were
synthesized by the OHSU Medicinal Chemistry Core Facility.
diABZI was obtained from MedChem Express. Puromycin was
obtained from Invivogen and used at 3µg/mL in resistant cell
culture. Steady-Glo cell lysis/luciferin and CellTiter-Glo viability
assay kits were obtained from Promega. Lipofectamine 3000
was obtained from Invitrogen. Sources and concentrations of
antibodies used against the following antigens are indicated
in parentheses: glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) (SC-51906; Santa Cruz) (1:10,000), IRF3 (4302; Cell
Signaling), human phospho-IRF3 (76493; Abcam), mouse IRF3
(SC-9082; Santa Cruz), mouse phospho-S379 IRF3 (79945S;
Cell Signaling), mouse phospho-S396 IRF3 (29047S; Cell
Signaling), STING (13647S; Cell Signaling), phospho-S366
STING (19781S; Cell Signaling), TBK1 (3504S; Cell Signaling),
phospho-TBK1 (5483S; Cell Signaling), NF-kB P65 (SC372;
Santa Cruz), NF-kB P50 (3035; Cell Signaling), GM-130
(610823; BD Biosciences).
Cell Line Cultures and Virus
Telomerase-transduced human foreskin fibroblasts stably
transduced with the IFN-responsive pGreenFire-ISRE lentivector
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FIGURE 12 | Comparison of transcriptomic changes in PBMCs induced by M04, LPS, and cGAMP. (A) Volcano plots illustrating −log10(p value) and fold change of
significantly differentially regulated transcripts for indicated stimulus relative to cells exposed to DMSO vehicle treatment. Gene symbols of the top 15 transcripts as
determined by Manhattan distance are labeled; (B) Venn diagram illustrating patterns of similarity in indicated stimulus-specific upregulated transcripts; (C) Fold
change correlation of all detected transcripts between indicated stimuli. Pearson correlation coefficient (r) presented for each comparison.
(System Biosciences) were used as previously described (18, 19).
A549 and HEK293T cells were a gift from Jay Nelson (Oregon
Health and Science University). MonoMac6 (MM6) cells were
a kind gift from Michael Gale (University of Washington)
and used as described (17). THP-1-ISG-Lucia and RAW-
ISG-Lucia were obtained from Invivogen. HEK293T, A549,
THF, and RAW264.7 cells were maintained in Dulbecco’s
modified Eagle’s medium (DMEM) containing 10% fetal bovine
serum (FBS), penicillin (100 U/ml), and streptomycin (100
U/ml) and were transduced with a lentivector containing
the pGreenFire ISRE cassette. THP-1 and MM6 cells were
maintained in RPMI 1640 medium supplemented with 10%
FBS, penicillin (100 U/ml), streptomycin (100 U/ml), and
HEPES (10mM). THP-1 ISG-lucia cells were differentiated
by 2 h of treatment with 100 ng/mL PMA, and then the PMA
was removed and replaced with complete medium for 72 h of
incubation prior to all assays. All cells were grown at 37◦C
and 5% CO2. Sendai virus (SeV) was obtained from Charles
River Laboratories and used at 160 hemagglutination units
(HAU)/ml. Human cytomegalovirus was grown and titered
as described (68) and exposed to cells at a multiplicity of
infection (MOI) of 3 unless otherwise indicated. cGAMP was
transfected into cells using Lipofectamine 3000 following the
manufacturer’s protocol.
CRISPR/Cas9-Mediated Genome Editing
and Ectopic Gene Expression
Genome editing using lentivector-mediated delivery of
CRISPR/Cas9 components was performed as described
previously (17–19). Briefly, we used the lentiCRISPRv2 vector (a
gift from Feng Zhang; Addgene plasmid # 52961) (69). STING-
specific guide RNAs (gRNA) were cloned into this vector (mouse
STING gRNA: AGTATGACCAGGCCAGCCCG; human STING
gRNA: CCCGTGTCCCAGGGGTCACG) and was then used
to transduce the appropriate cells, selected using puromycin,
and knockout validated by immunoblot. Stable and transient
expression of hSTING variants was done by cloning target ORFs
into the pLVX-EIF1α vector. Cells were then transduced and
selected for antibiotic resistance as described previously (70).
Transient transfection of these vectors into HEK293T cells was
done using Lipfectamine 3000 according to the manufacturer’s
protocol (Invitrogen).
Luciferase Reporter Assay and Type I
Interferon Bioassays
For reporter assays cells (THF-ISRE, RAW264.7-ISG-Lucia,
THP-1-ISG-Lucia) were plated in white 96-well plates 24 h before
stimulation. Treatments were performed in quadruplicate in
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50 µL of either DMEM or RPMI plus 2% FBS overnight unless
otherwise indicated. Steady-Glo lysis/luciferin reagent (Promega)
was added (1:1 [vol/vol]) to each well, and luminescence
was measured on a Synergy plate reader (BioTek). For cell
viability assays, CellTiter-Glo reagent was used following the
manufacturer’s suggested protocol. For type I IFN bioassays, cells
of interest were plated at 50,000 cells/well in 24-well-plates and
serum starved in X-Vivo15 medium for 1 h prior to treatment.
After treatment for 24 h, the media was harvested and clarified
at 10,000 x g for 3min. Recombinant IFNβ (at 40, 20, 10, 5, 2.5,
1.25, and 0.63 U/ml) was used to generate a standard response
curve. The supernatant or standard was then added to THF-
ISRE-1IRF3 cells (do not respond to STING/IRF3-inducing
stimuli) plated as described above for 8 h, and luminescence was
measured. IFN was quantitated by curve fitting relative to the
signals generated from the standards.
Immunoblotting
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) and immunoblotting were performed as follows. After
cell pelleting at 2,000 × g for 10min, whole-cell lysates were
harvested in RIPA lysis buffer (50mM Tris-HCl [pH 8.0],
150mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, and 0.1%
SDS) supplemented withHalt protease and phosphatase inhibitor
cocktail (Thermo Fisher). Lysates were electrophoresed in 8%
polyacrylamide gels and then transferred onto polyvinylidene
difluoride (PVDF) membranes (Millipore) by semidry transfer at
15VmA for 15min. The blots were blocked at room temperature
for 2 h or overnight, using 5% non-fat milk in PBS containing
0.1% Tween 20. The blots were exposed to primary antibody
in 5% non-fat milk in PBS containing 0.1% Tween 20 for 18 h
at 4◦C. The blots were then washed in PBS containing 0.1%
Tween 20 for 20, 15, and 5min, followed by deionized water
for 5min. A 1-h exposure to horseradish peroxidase-conjugated
secondary antibodies and subsequent washes were performed as
described for the primary antibodies. Antibodies were visualized
using enhanced chemiluminescence (Pierce).
Indirect Immunofluorescence Assay
For the indirect immunofluorescence assays (IFA), cells were
grown on coverslips in 24-well-plates and treated as described
above. At room temperature, cells were washed twice with
PBS, fixed for 30min in 3.7% formalin, washed, and quenched
for 10min using 50mM NH4Cl. Cells were permeabilized
with 0.1% Triton X-100 for 7min and washed three times
with PBS containing 2% bovine serum albumin (BSA). Cells
were incubated with primary antibody in PBS containing
2% BSA at 37◦C for 1 h, washed three times in PBS
containing 2% BSA (10min for each wash), and incubated with
fluorescently conjugated secondary antibody diluted 1:1,000 in
PBS containing 2% BSA for 1 h. Cells were washed twice in PBS
containing 2% BSA (10min for each wash) and once in PBS.
Coverslips were mounted on a microscope slide with Vectashield
mounting medium (Vector Laboratories, Burlingame, CA)
containing DAPI, and imaging was performed on an Evos cell-
imaging system.
RNA Isolation and Semiquantitative
Reverse Transcription-PCR
Total RNA was isolated from cells, treated with the DNase
provided in a DNA-free RNA isolation kit (Zymo Research)
according to the manufacturer’s protocol, and quantified by UV
spectrometry. Single-stranded cDNA for use as a PCR template
was made from total RNA and random hexamers to prime first-
strand synthesis via a RevertAid First Strand cDNA synthesis
kit (Thermo Fisher). Comparison of mRNA expression levels
between samples was performed using semiquantitative real-time
reverse transcription-PCR (qPCR) with an Applied Biosystems
sequence detection system according to the 11CT method
(71), with GAPDH as a control. Prevalidated Prime-Time 6-
carboxyfluorescein qPCR primer/probe sets obtained from IDT
were used for all genes.
STING Protein Purification and Thermal
Shift Assays
Assays of the molecular interaction between the purified human
STING C-terminal domain (amino acids 137 to 379; non-
transmembrane domain) and M04 were performed as previously
reported (19). Briefly, the 6xHis STING CTD open reading
frame was cloned into pRSET-B (Invitrogen) and used to
transform the Escherichia coli strain pLysS (Promega). The
transformed E. coli cells were then induced to express the protein
as induced by 1mM IPTG (isopropyl-D-thiogalactopyranoside)
at 16◦C for 18 h. STING protein was purified by nickel-
affinity chromatography (Clontech Laboratories) and then
further purified by gel filtration chromatography (HiPrep 16/60
Sephacryl S-100 HR column; GE Healthcare Life Sciences).
Eluted proteins were concentrated using Amicon centrifugal
filters (10-kDa cutoff). For thermal shift assays, SYPRO Orange
dye was used, following the manufacturer’s suggested protocol,
to determine protein stability in the presence and absence of
cGAMP (Invivogen) or M04.
Human Samples
Peripheral blood mononuclear cells (PBMCs) were collected
and analyzed at two separate institutions for cytokine secretion
measurements, maturation marker analysis, and cross-priming
assays. All procedures were performed accordance with the
Institutional Review Boards of the respective institutions (Drexel
University College of Medicine, Earle A. Chiles Research
Institute). Donor samples analyzed at Drexel University were
obtained fromMartin Health System (Stuart, Florida). The study
was approved by the Institutional Review Board of Martin
Health System and Drexel University College of Medicine
(Philadelphia). All donors signed informed consent from all
participants. Patients with locally advanced or borderline
resectable pancreatic cancer enrolled on a clinical study (46)
provided a pre-treatment blood sample. Studies were approved
by the institutional review board at Providence Portland Medical
Center, Portland OR with study ID numbers PHS 10-141B
and PHS 13-026A. The clinical trial registration numbers are
NCT01342224 and NCT01903083. All patients provided written
informed consent for treatment and participation in these
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studies, including analysis of serum and blood parameters over
the course of the study.
Luminex Analysis
PBMCs were plated at 4 × 105 per well in 96-well-plates,
stimulated with DMSO, M04 (50µM), LPS (100 ng/mL), or
cyclic-di-AMP (10µg/mL) diluted in RPMI, and incubated
at 37◦C and 5% CO2 for 24 h. Supernatants were then
removed and used in a multiplex cytokine bead-based assay
according to the manufacturer’s protocol (BD Biosciences human
inflammation cytokine bead array, catalog number 551,811,
or BioLegend human IL-12p70 enzyme-linked immunosorbent
assay [ELISA] Max).
Generation of Human Monocyte-Derived
Dendritic Cells (mDCs)
Human PBMCs from healthy donors were obtained immediately
after blood withdrawal using the Ficoll-Paque (GE Healthcare)
gradient method and stored in liquid nitrogen until usage.
Cells were thawed in RPMI 1640 (Corning) supplemented
with 10% fetal bovine serum (Access Biologicals) and 1%
penicillin/streptomycin (Gibco). CD14+ CD16+ monocytes
were then enriched from total PBMCs by negative selection
using the EasySepTM human monocyte enrichment kit without
CD16 depletion (STEMCELL Technologies) according to
the manufacturer’s protocol and counted. Cells were then
resuspended in serum-free CellGenix GMP dendritic cell
medium (CellGenix) with 100 ng/ml of recombinant human
GM-CSF (BioLegend) and 20 ng/ml of recombinant human IL-4
(Gemini Bio-Products) at a density of 2 × 106 per ml in 24-well
plates. After 48 h of incubation, cells were stimulated with 0.5
ug/ml of LPS (Invivogen) plus 40 ng/ml of IFNγ (Gemini Bio-
Products) in medium or with two concentrations 25 and 50uM
of the STING agonist MO4 (source) in DMSO, and compared to
the DMSO control. Dendritic cells were harvested after 24 h of
stimulation, and analyzed by flow cytometry.
Flow Cytometric Analysis of Stimulated
Human mDCs
Harvested mDCs were incubated with TruStain FcγR block
(BioLegend) and fluorochrome-conjugated antibodies for
15–20min on ice in the dark. The following BioLegend
fluorochrome-conjugated anti-human antibodies were used:
CD3 (clone HIT3α), CD19 (clone HIB19), CD14 (clone M5E2),
CD11c (clone 3.9), HLA-DR (clone L243), CD86 (clone IT2.2),
CD83 (clone HB15e), CD40 (clone 5C3), and CD80 (clone
2D10). Dead cells were identified using both LIVE/DEAD
fixable Aqua Dead Cell Stain Kit for flow cytometry (Vivid) (Life
Technologies) and Annexin V (BD Biosciences). mDC samples
were washed then resuspended in PBS plus 2% FBS then acquired
on a BD LSR II and analyzed with FlowJo software (Treestar).
The gating strategy excluded doublet cells and mDCs were gated
on live (Vivid− Annexin V−) CD3− CD19− CD11c+ cells.
Peptides
The HLA-A2-restricted Melan-A/ MART-1 modified peptide
(ELAGIGILTV, residues 26-35A27L) was used for in vitro priming
and was obtained from Biosynthesis. The tetramer HLA-
A∗02:01- ELAGIGILTV (Melan-A/MART-1) was obtained from
the NIH Tetramer Core Facility (Emory University).
In vitro Priming of Naive Melan-A/MART-1
Ag-Specific CD8+ T Cells
Naïve CD8+ T cells precursors for theMelan-A/MART-1 epitope
ELAwere primed in vitro using unfractionated PBMCprotocol as
described in [1] with minor modifications. Briefly, PBMC from
HLA-A2+ healthy donors were thawed and seeded at 5 × 106
cells/ml in CellGro R© DC medium (CellGenixTM), supplemented
with human GM-CSF (100 ng/ml; MACS Miltenyi Biotec) and
IL-4 (20 ng/ml; Gemini Bio-products) in a 24-well tissue culture
plate. After 24 h, Melan-A/MART-1 antigen (at 10µg/ml) was
added, in presence of M04 (final 50µM) or 2’3’cGamp (5µg/ml,
Invitrogen) to induce maturation of resident dendritic cells.
Twenty-four hours later and every 3 days, half of the media
was replaced by fresh RPMI 1640 (Corning) supplemented with
8% human serum (Atlanta Biologicals) and IL-2 (20 U/ml,
Miltenyi Biotech). On day 11, the CD8+ T cells frequency and
were assessed by flow cytometry within the CD3+CD8+ T cell
population using Melan-A –HLA-A2 tetramer staining after
exclusion of dead cells.
In vivo Administration of M04
All animal procedures for in vivo administration of M04 were
conducted in accordance with and approved by the Oregon
Health and Science University Institutional Animal Care and
Use Committee (IACUC) under protocol 0913. The Oregon
Health and Science University IACUC adheres to the NIH
Office of Laboratory Animal Welfare standards (OLAW welfare
assurance A3304-1). C57BL/6J mice (5–7 weeks of age; Jackson
Laboratories) were housed in cage units, fed ad-libitum, and
cared for under USDA guidelines for laboratory animals. M04
at 25 mg/kg of body weight or DMXAA (or DMSO alone)
was prepared in DMSO plus PBS to 200 µL and injected
intraperitoneally. Animals were euthanized at 5 h post-injection
by isoflurane overdose. Spleens were harvested, RNA isolated,
and qPCR performed as described above.
RNA-seq
PBMCs from two healthy adult donors were obtained from
StemCell Technologies, grown in 12 well-dishes in RPMI +
10% FBS, and treated in duplicate for 6 h with 1% DMSO
vehicle, 50µMM04, 100 ng/mL LPS, or 15µg/mL cGAMP. Total
RNA was isolated using Direct-zol RNA mini-prep kit (Zymo
Research) in accordance with manufacturer’s instructions and
profiled for intactness on a Bioanalyzer (Agilent). Libraries were
then prepared using the Tru-Seq RNA Sample Preparation kit
(Illumina). Briefly, poly(A)+ RNA was isolated from 500 ng
of total RNA per sample. The isolated RNA was fragmented
using divalent cations and heat. First strand cDNAwas generated
using randomhexamer priming. The RNA template was removed
and the second strand was synthesized. The ends of the
cDNAs were repaired, followed by adenylation of the 3′ termini.
Indexing adapters were ligated to the cDNA ends. The ligation
products were amplified using polymerase chain reaction (PCR).
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The amplification product was cleaned using AMPure XP beads
(Beckman Coulter). Libraries were profiled on the Tapestation
2200 (Agilent). The concentration of the libraries was determined
using real time PCR on a StepOne or StepOnePlus Real Time
PCR Workstation (Thermo) using a library quantification kit
(Kapa Biosystems). Samples were mixed for multiplexing and
run on a HiSeq 2500 (Illumina) using a 100 cycle single read
protocol. Base call files were converted to fastq format using
Bcl2fastq (Illumina).
Gene Expression and Transcription Factor
Prediction Analysis
The quality of the raw sequencing files were first evaluated using
FastQC combined with MultiQC (72) (http://multiqc.info/). The
files were imported into the Oregon National Primate Center’s
DISCVR-Seq, LabKey (73) server-based system, PRIMe-Seq.
Trimmomatic (74) was used to remove any remaining Illumina
adapters. Reads were aligned to the Homo_sapiens.GRCh38
genome in Ensembl along with its corresponding annotation,
release 84. The program STAR (v020201) (75) was used to align
the reads to the genome. STAR has been shown to perform
well-compared to other RNA-seq aligners (76). Two-pass mode
was used with default parameters. Since STAR utilizes the gene
annotation file, it calculated the number of reads aligned to
each gene. RNA-SeQC (v1.1.8.1) (77) was utilized to ensure
alignments were of sufficient quality. Samples had an average
of 45M mapped reads, an average exonic rate of 83%, and an
average of 22K genes detected (>5 reads) per sample. Gene-
level raw counts were normalized using DEseq2 (78) which were
then transformed using regularized log transformation (rlog) to
stabilize variance in R. After data processing, gene-wise general
linear models with compound symmetry covariance structure
was used (to account for repeated response measures on the same
subject) to identify differentially expressed genes in SAS9.4. We
used criteria to designate genes as differentially regulated in each
stimulus vs. control with fold change ≥ 2 (up or down) and raw
p < 0.05. Transcription factor prediction analysis was performed
by submitting all genes found to be significantly upregulated by
M04 to the online tools PASTAA and RegulatorTail (48, 49) using
default settings. Venn diagrams were made using BioVenn (79).
Volcano plots were made using VolcanoNoseR (https://huygens.
science.uva.nl/VolcaNoseR/).
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